Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (13329)	1/16/1998 12:51:00 PM
From: Vector1	Read Replies (2) \| Respond to of 32384

Andreas, I know the technical folks think they can call dips, but I think it is very difficult. I think the stock has an excellent long term risk reward profile at these levels. Could the stock go lower. Of course it could especially is there is any delay with the FDA or a diappointing clinical. Also although I am a major LGND bull and have a substantial position I would point out that this is a speculative stock and by no means a sure winner. There is an enormous amount even the LGND scientists don't know about Targretin and Panretin and exactly how they interact with the various diseases they are being asked to attack. The two primary areas they are going after, cancer and metobolic disease are enormously complicated and there are numerous examples of promising drugs that have failed in these areas despite early promise. If you already have 1/3 of your portfolio in LGND i would not rec additional purchaces. V1